HUTCHMED (China) Limited
NASDAQ:HCMDrug Manufacturers - Specialty & Generic
+$0.16 today
- Market cap
- $2.44B
- Beta
- 0.37
- P/E (TTM)
- 46.2
- EPS (TTM)
- $0.05
Volume 0.04M
Average 0.04M
HCM Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
HUTCHMED (China) LimitedNASDAQ: HCM
Research & Development · Q2 FY2025 · quarter ended Jun 2025
Research & development declines year over year
Q2 FY2025 research & development of $36M fell 24.4% year over year, ahead of the -25.1% change in trailing-twelve-month research & development. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -15.0% a year.
Context
- Research & development amounted to 29.8% of revenue in FY2025, down 4.0 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -24.4% holds above the trailing-twelve-month pace of -25.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 164.15M USD
- Year-over-year change
- -23.1%
- 4-year CAGR
- -5.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 164.15M | -23.1% |
| FY2024 | 2024-12-31 | 213.37M | -29.6% |
| FY2023 | 2023-12-31 | 303.06M | +13.3% |
| FY2022 | 2022-12-31 | 267.59M | +29.0% |
| FY2021 | 2021-12-31 | 207.45M | — |
Research & Development vs competitors
How HCM compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -25.1% is the lowest of 9, against a peer median of +2.8%.
- Research & development amounts to 31.6% of revenue for HCM, versus a peer median of 67.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €2.18B EUR | -0.6% | +9.6% | 82.6% | |
| LTM Jun 2026 | $2.15B USD | +9.1% | +8.9% | 37.0% | |
| LTM Jun 2026 | $1.78B USD | — | -34.5% | 43.1% | |
AAPGAscentage Pharma Group International | FY2025 | CN¥1.08B CNY | +14.4% | +13.4% | 194.0% |
| LTM Jul 2026 | $824.32M USD | -6.8% | -2.6% | 33.8% | |
| LTM Jun 2026 | $497M USD | +2.5% | +22.0% | 424.8% | |
| LTM Sep 2026 | $378.58M USD | -9.4% | +7.3% | 27.9% | |
| LTM Mar 2026 | $339.54M USD | +5.2% | +52.0% | 150.7% | |
| LTM Jun 2026 | $236.92M USD | +3.2% | -8.3% | 52.7% | |
| LTM Jun 2025 | $190.1M USD | -25.1% | -15.0% | 31.6% | |
| LTM Jun 2024 | $56.93M USD | — | -15.5% | 877.1% | |
| Peer median (excluding HCM) | — | +2.8% | +8.1% | 67.6% | |
Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 356.13M | 426.41M | 838M | 630.2M | 549.96M |
| Cost of Revenue | 258.23M | 311.1M | 384.45M | 348.88M | 337.24M |
| Gross Profit | 97.89M | 115.31M | 453.55M | 281.32M | 212.72M |
| Gross Margin | 27.5% | 27.0% | 54.1% | 44.6% | 38.7% |
| Research & Development | 207.45M | 267.59M | 303.06M | 213.37M | 164.15M |
| Selling, General & Admin | 127.13M | 136.11M | 133.18M | 112.91M | 103.3M |
| Operating Expenses | 426.21M | 523M | 436.23M | 321.93M | 267.45M |
| Depreciation & Amortization | 7.19M | 8.66M | 8.21M | 12.34M | 13.34M |
| EBITDA | (207.96M) | (401.11M) | 26.58M | (31.36M) | (41.38M) |
| EBITDA Margin | -58.4% | -94.1% | 3.2% | -5.0% | -7.5% |
| Operating Income | (328.32M) | (409.77M) | 18.38M | (43.71M) | (54.73M) |
| Operating Margin | -92.2% | -96.1% | 2.2% | -6.9% | -10.0% |
| Interest Income | 2.08M | 9.6M | 36.15M | 40.08M | 50.01M |
| Interest Expense | 592K | 652K | 759K | 2.87M | 2.87M |
| Other Income / Expenses | 173.19M | 51.52M | 87.23M | 89.07M | 577.45M |
| Income Before Tax | (155.33M) | (360.24M) | 105.6M | 45.36M | 522.72M |
| Pre-Tax Margin | -43.6% | -84.5% | 12.6% | 7.2% | 95.0% |
| Income Tax Expense | 11.92M | (283K) | 4.51M | 7.19M | 63.78M |
| Net Income | (194.65M) | (360.84M) | 100.78M | 37.73M | 458.12M |
| Net Margin | -54.7% | -84.6% | 12.0% | 6.0% | 83.3% |
| EPS (Basic) | (1.25) | (2.15) | 0.60 | 0.22 | 2.65 |
| EPS (Diluted) | (1.25) | (2.15) | 0.60 | 0.22 | 2.60 |
| Weighted Avg Shares | 158.54M | 169.43M | 169.93M | 171.07M | 171.66M |
| Weighted Avg Shares (Diluted) | 158.54M | 169.43M | 173.84M | 174.57M | 174.58M |
HUTCHMED (China) Limited
NASDAQ:HCM
Intrinsic Alpha fair value
Locked
Current Price
$13.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.